Who is involved in this event?
This analytical, thought-provoking endeavor is designed to be useful to
  • SBIR Awardees from the very early-stage firm, through to te more mature firms seeking follow-on rounds.
    		•
    Though all Presentation Slots are now allocated, if raising capital is in your future, plan to participate.
  • Investors, seeking useful deal-opportunities from among this important group of pre-qualified firms.
    		•
    If you are such an investor, to maximize the value of your event participation, you may want to consider sponsorship.
    Session description: Day 1
    Session description: Day 2
    Setting this Event in context:
    Being SBIR-involved is probably not the primary reason that over TEN percent of current awardees are VC funded. However, the fact of that high percentage of all recent VC commitments having involved SBIR firms, speaks directly to the close connection between these two different, but important, forms of financial support tapped by so many SBIR-involved firms.
         In that context, this event is carefully designed to address TWO primary objectives. Specifically, the effort is
    to provide the structured setting in which     pre-qualified, Venture Capital-seeking SBIR Awardees can interact with various interested investors.
         Participating investors represent established VC Funds, Corporate VC entities and a few organized Angel Investors. Most have been already involved with SBIR-active firms and/or have expressed serious interest in making these types of investments.
    to offer participating SBIR Awardees - to include a few perhaps not quite yet ready for the full-blown effort of raising money -- a sophisticated and useful learning experience directly related to the task of raising capital.
         These working sessions address the mechanics and the detail of the equity-raising endeavor. Issues in     term sheet development and valuation, for example, will be discussed, along with the elements of a VC IP due diligence process, and careful consideration of the present state of capital markets and how that affects choices.
    Synoposis
    Thursday MARCH 16, 2006 Session description: Day 1
    Time Session Title and Description
    8:00 AM
    		 Registration
    9:00 AM Pre-Event Working Session: The VC Eligibility Issue
    Headed up by two long-time, leading SBIR advocates nationally, this Pre-event RoundTable discussion -- open to all Event registrants -- will provide some of the background to the highly controversial SBIR-VC Eligibility issue.
         While explicitly NOT the focus of this Event, fallout from this highly contentious issue - which has been ongoing now for a very long time - has been/is part of the backdrop against which the primary focus of this Event is being conducted - that of bringing together growth-oriented SBIR Awardees with the sources of capital needed to sustain that business development.
         The approach here is not be to take sides, nor to argue the case for - or against - the issue as posed by the proposed legislation offered by BIO/NVCA. Instead, the effort is to get to workable recommendations for expedited resolution.
         If that is your inclination, plan to participate in this working session.
    Session leaders Jere Glover, former SBA Chief Counsel for Advocacy, now Executive Director, Small Business Technology Coalition
    Ann Eskesen, Innovation Development Institute
    10:00 AM

    Main Conference begins:

    Opening remarks

    This later than usual start is designed to provide many out-of-state participants the option of an early morning flight. limiting their out-of-office time and incurred accommodation costs.
    10:05 AM Examining the Form and extent of VC-SBIR Activity:
    Speaker/
    Discussants    		 Ann Eskesen, Innovation Development Institute Format: Context-Setting presentation
    Focus and objective: From the very earliest days of SBIR following passage of the enabling legislation in 1983, there has been close connection between SBIR and Venture Capital. A significant percentage of Awardees in every SBIR agency have been/are VC funded at some level. Drawing down on the exquisitely detailed SBIR Awardee databases developed and maintained from the outset by the Innovation Development Institute, this session will examine various aspects of this important condition.
    10:40 AM Recent trends in US VC activity: geographic distribution and industry focus. What does that tell us?
    Speaker/
    Discussants    		 Ian Carver, PriceWaterhouseCoopers Format: analytical presentation
    Focus and objective: Now in its 12th year, the MoneyTree™ Survey is a quarterly study of venture capital investment activity in the United States. As a collaboration between PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association, it is the only industry-endorsed research of its kind. The MoneyTree Survey is the definitive source of information on emerging companies that receive financing and the venture capital firms that provide it. The issued studies are a staple of the financial community, entrepreneurs, government policymakers and the business press worldwide.  
    11:05 AM
    		 Angel Investors: what makes them special?
    Speaker/
    Discussants    		 John J (Jay) Schwartz,
    Stage 1 Strategies, LLC, Newton, MA    		 Format: Working presentation
    Focus and objective: Business Angels are a hugely important part of the equity capital condition. Many SBIR Awardees needing external capital find whatthye need from among these smaller-scale, private investors.
         These days, in many areas of the country, individual private investors are grouping together both to share information and, in some cases, to leverage on their personal commitment by making group investment. The featured speaker is very active in one such organization - the Keiretsu Forum. Others are involved in this Event
         The focus of this session will be to discuss --- When does Angel financing make sense? What is different about the Angel deal? and, thereby, about the presentation that will resonate well with this type of investor?
    11:25 AM First set of In-A-Nutshell Presentations
    Overview to all the Nutshell Presentations:
    From the more than 70 currently-active SBIR Awardees who originally submitted for a Presentation Slot at this SBIR-VC Event, a total of FORTY-FOUR were eventually selected. For those allocated a Full-Presentation Slot, part of their commitment/ challenge is a 5-minute presentation in Plenary Session synopsizing their Business Opportunity in a Nutshell.
    Note that, unfortunately, due to unforeseen circumstances, two Full-Presentation presenters cannot be present. Their materials are in the Package and on the Event CD.

    Grouped by Presentation Type, the Nutshells from all Fourty selected firms are included in the Event Package. To allow the audience readily to keep track of all these presentations, they are offered in alphabetical order by the name of the Presenting Firm.
    Time allocation will be strictly enforced.

    Session Moderator: Lawrence S. Nannis, Levine, Katz, Nannis & Solomon, PC, Needham, MA
    Presenting Firms in order:
     
    • Amyxa Pharmaceuticals, Woburn, MA
    • Aonex Technologies Inc, Pasadena, CA
    • Argus Medical Inc, Bethesda, MD
    • BioMedical Research Models Inc, Worcester, MA
    • Biosomes Inc, Wilmington, DE
    • Cambria Biosciences LLC, Woburn, MA
    • ComSense Technology Inc, Cleveland, OH
    12:05 Noon Buffet Luncheon
    1:15 PM The phenomenon of SBIR spin-off:
    Speaker/
    Discussants    		 Robert Kline-Schroder, Creare Inc
    Oliver Murphy, Lynntech Inc
    Gordon Drew, Physical Optics Corporation (POC)     		Format: Talk-Show
    Focus and objective: Particularly among Awardees who have been extensively involved in the SBIR-STTR programs - the large volume winners - the use of spin-off has become a primary vehicle among SBIR-involved firms to achieve market penetration.
        In an unscripted panel-session involving the principals of a number of firms who have already used this approach - some, multiple times - how that has worked, problems as well as successes and issues that have had to be addressed will be examined
    1:45 PM Second set of In-A-Nutshell Presentations
    Again, in alphabetical order by the name of Presenting Firm, these are a series 5-minute presentations synopsizing in a Nutshell the Business Opportunity of Full-Presentation firms
    Time allocation will be strictly enforced.

    Session Moderator: Aleksandar Mollov, Keiretsu Forum Boston, Boston, MA
    Presenting Firms:
     
    • Cornerstone Pharmaceuticals Inc, New York, NY
    • CryoFacets Inc, Raleigh, NC
    • EP Limited, Somerville, MA
    • Gibbard Research and Development Corporation, Haverhill, MA
    • Guardian Solutions Inc, Bradenton, FL
    • ImTelligenceŽ Inc, East Hartford, CT
    2:20 PM Staying within the rules: positioning the firm to achieve and maintain full and effective SBIR involvement. Two important issues
    SBIR is designed to provide some level of protection to small firms initially against the full rigors of the federal procurement process. However, as a small firm proceeds within the program, the fact of being federally-funded brings its own set of requirements. At this level, SBIR operates within a range of rules and regulations, some specific to the program, a few particular to the agency, most within the larger context of the FAR - Federal Acquisition Regulations - which define federal procurement activity.
       Misunderstanding the complexity and nuance of these factors or simply ignoring their existence, can create a range of unintended, and potentially very serious consequences.
        Involving two highly-qualified players, this session will address two particuarly critical issues for growth oriented, small firms.- that of retaining ownership of SBIR-funded IP and of maintaining SBIR eligibility when in receipt of equity financing.
    Topic One Rights to government-funded inventions made under the SBIR-STTR programs
    Speaker/
    Discussants    		 Jacob (Jesse) N. Erlich, Burns & Levinson, LLP
    Focus and objective: Offered by the former Chief Patent Advisor for the US Air Force now in private practice, this presentation will address the important issue of ownership rights on subject inventions which fall under the SBIR-STTR programs. Carefully examined will be the detail of differentiating between ownership rights which accrue to the SBIR Awardee and those held by the government. Distinguishing between inventions which come out of what the government funded versus those which are developed from other sources, the emphasis will be on how to identify and to protect ownership of inventions which fall outside the scope of the SBIR-STTR award effort.
    Topic Two Structuring external financing to maintain compliance with SBIR size standards: factors to consider
    Speaker/
    Discussants    		 Jere Glover, Brand and Frulla LLP & Executive Director, Small Business Technology Coalition (SBTC), Washington, DC
    Focus and objective: Offered by the former SBA Chief Counsel for Advocacy in the Clinton Administration and now heading up the primary organization in Washington DC monitoring SBIR-related issues (SBTC), this session will address the critically important issue of maintaining SBIR eligibility when growth of the firm involved raising external capital.
    3:00 PM
    Refreshment break
    3:20 PM Third set of In-A-Nutshell Presentations
    In alphabetical order by the name of Presenting Firm, these are a series 5-minute presentations synopsizing in a Nutshell the Business Opportunity of Full-Presentation firms
    Time allocation will be strictly enforced.

    Session Moderator: Gregory Milman, NIAID, National Institutes of Health, Bethesda, MD
    Presenting Firms:
     
    • INCELL Corporation LLC, San Antonio, TX
    • Kinetic Muscles Inc, Tempe, AZ
    • Microvi Biotech LLC, Overland Park, KS
    • Nanocopoeia Inc, St. Paul, MN
    • Nobex Corporation, Research Triangle Park, NC
    • Phylogenetix Laboratories Inc, Overland Park, KS
    • RemoteReality Corporation, Westborough, MA
    4:00 PM Keeping out of Trouble: learning from the top ten mistakes most commonly made by early-stage companies
    Speaker/
    Discussants    		 Joseph S. Ayoub, Jr, Nutter, McClennen & Fish, LLP Format: Working session
    Focus and objective: Though structured in the manner of Dave Letterman's Top Ten, this very serious working session is designed perhaps to enable participating BSIR firms to avoid some of the most obvious mistakes often made by early-stage small firms. The very experienced presenter will draw down on the considerable case-experience of several advisors to early-stage, technology-based small firms.
    4:25 PM Fourth set of In-A-Nutshell Presentations
    By alphabetical order by the name of Presenting Firm, these are a series 5-minute presentations synopsizing in a Nutshell the Business Opportunity of Full-Presentation firms
    Time allocation will be strictly enforced.

    Session Moderator: Adi R. Guzdar, Aguzdar Consultants, Framingham, MD
    Presenting Firms:
     
    • Securics Inc, Colorado Springs, CO
    • Tailored Materials Corporation, Tucson, AZ
    • TPL Inc, Albuquerque, NM
    • Versatilis LLC, Shelburne, VT
    • Vista Engineering Inc, Birmingham, AL
    • Wang Electro-Opto Corporation, Marietta, GA
    • Zweave Inc, Boston, MA
    5:05 PM Translating R&D into Real Applications: how to find good, early markets and customers for New Technology
    Speaker/
    Discussants    		 Barry Unger, Boston University Format: Interactive Workshop
    Focus and objective: The perennial business challenge for those engaged in cutting edge science and technology research, finding early applications that can be readily and economically commercialized. The problem is compounded when especially when the applications are largely unknown at the time of the innovative research, or when one is making an effort to expand into new areas beyond that of the customer (e.g. a government agency) that paid for the initial R&D.
        Sometimes this is referred to as market research. In practical terms, however, it is better defined as market "search".
        In this session useful concepts to guide this process such as market segmentation and stakeholder analysis will be defined and discussed. After this brief introduction, members of the audience will be invited to share their experiences with approaches for getting the data necessary to become aware of potential application opportunities and to assess them, such as: a) attending and networking at vertical industry trade shows and talking to industry experts; b) telephone interviewing and cold calls to potential industrial users; c) doing a broad gauge campaign of press releases and articles targeted at a mix of industries thought to be sources of applications.
    5:45 PM Reception
    6:45 PM Nutter TechnoVation Awards:
    Award Ceremony & Awardee Presentations

    Established by Nutter McClennen & Fish, a leading Boston law firm, the Nutter TechnOvation Awards™ provide selected early-stage technology and life sciences companies from around the country with access to high quality legal services across a range of critical business areas - business organization, contract negotiation, financing strategies, intellectual property protection, licensing, securities law and other regulatory compliance, and tax considerations
            Chosen through a rigorous selection process from among applicant firm nationwide, TechnOvation Award recipients become Nutter clients and receive credits for a package of no-cost legal services. TechnOvation recipients can use the credits for those legal services most appropriate to their business needs. In addition to expert legal representation and counseling from within Nutter, awardees also have access to Nutter’s extended network of professional relationships for practical business advice, financial guidance, knowledge sharing, along with introductions to funding sources and strategic partnerships

    Session Moderator: Richard N. Kimball, Nutter, McClennen & Fish, LLP., Boston, MA

    Awards Ceremony to latest recipient of a TechnOvation Award™ Awards Ceremony to latest recipient of a TechnOvation Award Jeanne Dietsch, MobileRobots Inc.
    Awards ceremony to be followed by 3 minute Nutshell presentations discussing their business opportunity by FIVE of the most recent Nutter TechnOvation™ Awardees

  • Jeanne Dietsch, MobileRobots Inc., Amherst, NH
  • Jim Weldon, Abnaki Systems Inc., North Hampton, NH
  • David Holbrook, Walleye Technologies, Somerville, MA
  • Munther Dahleh and Sridevi Sarma, Infolenz, Inc., Cambridge, MA
  • Martin Bodley, Maestrolabs, Inc., Maynard, MA.
    Maestro cannot attend. They have opted to show a 3 minute video)
  • Award Presentation to most recent TechnOvation Recipient
  • Nutshell presentation equivalent by SIX small firms which have been in receipt of these awards
    • 7:15 PM Business Development Clinic:
    Featured company: TPL MicroPower Technologies, Albuquerque, NM
    Speaker/
    Discussants    		 Charles Lakeman, Presenter
    Panel being selected    		 Format: Live Case
    Focus and objective: Adapted from the MIT Enterprise Forum format, this session will feature a firm that is a start-up, spinning out of an SBIR-involved firm which has been program involved form the very earliest days of the event.
        In advance of the conference, management will have provided copies of their White Paper to a carefully selected group of experts who will serve as their panel and advisors. This paper will address issues with which the firm is currently dealing and into which they are seeking input.
        At the event, following a brief overview presentation by the firm referencing aspects of those concerns, the panel will provide their input. Audience participation is anticipated.
    8:30 PM Day's Events Conclude
    Synoposis
    Friday MARCH 17, 2006 Session description: Day 2
    Time Session Title
    7:30 AM Breakfast
    8:15 AM The NSF SBIR matching grant program
    Speaker/
    Discussants    		 T James Rudd Format: presentation
    Focus and objective: The National Science Foundation - the very first federal agency to have instituted in 1977 what became the pilot for SBIR program - has launched an effort to encourage and support external investment in their awardees. Designated SBIR Phase IIB, NSF will match a third-party investment in the NSF funded project to a maximum of $500K. This session will look at the detail of how this works.
    8:30 AM Okay ... you've made it to having the VC Term Sheet in your hands. What do all those clauses mean?
    Speaker/
    Discussants    		 Richard N. Kimball, Nutter, McLennen & Fish, LLP
    Alex Glovsky, Nutter, McLennen & Fish, LLP

    		 Format:Interactive Team session
    Focus and objective: Involving two highly experienced VC attorneys, this session will systematically examine some of the language which will almost certainly be in the Term Sheet prepared by your Venture Capitalist. Topics to be addressed will include
    • Typical deal structures
    • Shareholder/Investor Rights Agreements
    • Governance and control issues
    • Architecture of the Equity - Anti-dilution protection; Pre-emptive rights; Redemption rights and Registration rights
    • Equity compensation issues
    • What to Anticipate in Negotiations.
    9:10 AM Corporate Venture Capital: Myth, Mystery & Fact
    Speaker/
    Discussants    		 Adam Caper, Synchrony Venture Management
    Matthew Insley Growney, Motorola Ventures    		 Format:Interactive working session
    Focus and objective: Corporate Venture Capital has enjoyed a recent resurgence as the innovation landscape has flattened and become more open. CVC investment can offer a small firm the opportunity to build close ties with a valuable business partner, send a strong validating signal to the marketplace, and provide access to resources and complementary assets that it would never be able to generate on its own.
         But CVC investors have different requirements, processes and tempos than do financial venture capital investors, as well as an agenda that's a function of their company's core strategy. For companies considering whether to pursue financing options with CVCs, it pays to get a look at the world from their perspective.
         In this session, two CVC professionals will examine the role that CVC can play in helping companies succeed, and will share their perspectives to help you know what to expect when dealing with a potential corporate investor
    9:45 AM Preparing the IP portfolio for your First (or Next) Round of Funding.
    Speaker/
    Discussants    		 Ronald E Cahill, Nutter, McLennen & Fish, LLP Format: Analytical presentation
    Focus and objective: A critical factor both in raising external capital at all and in setting a valuation on that funding is grounded in the strength and effectiveness of firm's Intellectual Assets portfolio. If you don't own it, you can't trade with it, sell it or raise money with it. Far more than simply a mechanisms for protection, the bedrock of your growth strategy and business development options is how what what you own is defined.
        This very focused session will effectively go through the process of a VC Audit of IP related issues.
    10:05AM Refreshment Break
    10:20 AM Concurrent Mini Plenaries
    In these concurrent sessions, the SBIR Awardees selected for presentation are featured. Based on their applications, Presenting Firms have been allocated into one of two groupings.
    • Full Presentation: those SBIR Awardees - several already VC-funded at some level - which, based on received applications, judged ready to discuss the investment opportunity they represent.
    • Early-Stage firms: those SBIR Awardees - usually somewhat younger and smaller - which, based on received applications, were judged to have good potential but are not there yet. They are probably not ready fully to strut their stuff in pitch format. This very interesting group of companies will make shorter presentations seeking feedback and input in what is designed to be more of a workshop environment.
    Event-registered Venture Capitalists have had Pre-Event access to the one-two page Nutshells on all Presenters that are in all Event Packages. For Full-Presenting firms, the participating VCs have also had Pre-Event access to the more detailed, 8-10 page Executive Summaries submitted by these more mature firms.
    Full-Presentation Firms: Morning-THREE groupings

    In each morning session, FIVE selected fi rms have been allocated a total of TWENTY-FIVE minutes each. Approximate start-time for each Presenter is indicated. Brief transition period is built in.

    Each firm may use this time in whatever manner they choose. However, time allocations will be strictly enforced.
    Primary Presentations:
    FIVE featured firms each allocated a 25 minute slot Full-Presentation Session ONE:
    Location: George Washington Carver Room 202

    10:20 AM Moderator remarks: J. James Rudd, National Science Foundation, Arlington , VA

    • 10:25 AM Aonex Technologies Inc, Pasadena, CA; Robert G. L. Shorr, Presenter
    • 10:52 AM Versatilis LLC, Shelburne, VT; George Powch, Presenter
    • 11:20 AM Wang Electro-Opto Corporation, Marietta, GA; Johnson Wang, Presenter
    • 11:48 AM TPL Micropower Technologies, Albuquerque, NM; Charles Lakeman, Presenter
    • 12:15 PM Tailored Materials Corporation, Tucson, AZ; Charles Hassen, Presenter
    		Primary Presentations:
    FIVE featured firms each allocated a 25 minute slot. Full-Presentation Session TWO::
    Location: George Washington Room 302 (Third Floor)

    10:20 AM Moderator remarks: Gregory Milman, NIAID, National Institutes of Health, Bethesda, MD

    • 10:25 AM Cornerstone Pharmaceuticals Inc, New York, NY; Rob Shorr, Presenter
    • 10:52 AM Nobex Corporation, Research Triangle Park, NC; Kenneth James, Presenter
    • 11:20 AM INCELL Corporation LLC, San Antonio, TX; Mary Pat Moyer, Presenter
    • 11:48 AM EP Limited, Somerville, MA; Michael Curley, Presenter
    • 12:15 PM Nanocopoeia Inc, St. Paul, MN; Karen M. Arnold, Presenter
    		Primary Presentations:
    FIVE featured firms each allocated a 25 minute slot. Full-Presentation Session THREE::
    Location: Library (Third Floor)

    10:20 AM Moderator remarks: Robert J. Crowley, Massachusetts Technology Development Corporation, Boston, MA

    • 10:25 AM Biomedical Research Models, Inc., Worcester, MA; Dennis Guberski, Presenter
    • 10:52 AM Kinetic Muscles, Inc, Tempe, AZ; Ed Koeneman, Presenter
    • 11:20 AM Cambria Biosciences LLC, Woburn, MA; Leo Liu, Presenter
    • 11:48 AM Amyxa Pharmaceuticals, Woburn, MA; Trevor Castor, Presenter
    • 12:15 PM Argus Medical, Inc, Bethesda, MD; Alfredo Zarate, Presenter
    Roundtable Start-Up Clinic A
    Location: John Hancock Room 201    :
    With particular emphasis on the range of issues associated to the start-up, early-stage condition, by design this session is somewhat less tightly structured than full-blown presentation sessions in the time period.
    Each selected fi rm is assigned up to TWENTY minutes to make presentation, take questions and receive relevant feedback from the various funding sources and other professionals experienced in the start-up and early-stage condition. Again, the time allocation will be enforced and each presenter may use their time as they see fit.

    In this context, however, the Session Moderator and other professionals in the room have more fl exibility about how they run the session. Order of presentation will be retained but the amount of time between presentations may be longer with the balance of time used for working discussion of the common issues raised by the case presentations.

    10:30 AM Moderator remarks: Lawrence S. Nannis, Levine, Katz, Nannis & Solomon, PC, Needham, MA

    Presenting Firms:
    • Intelligent Automation, Inc, Rockville, MD; Eric van Doorn, Presenter
    • Prodyne Corporation, Newton, MA; Steven Africk, Presenter Af
    • CostVision Inc., Boulder, CO; Charlie Stirk, Presenter
    • Chromis Fiberoptics LLC, Warren, NJ; Whitney White, Presenter
    • Freight Pipeline Company, Columbia, MO; Henry Liu, Presenter

    12:45 PM Luncheon: Robert E. Perry Room 303
      The Future of Venture Capital
    Speaker/
    Discussants    		 Josh Lerner, Harvard Business School Format: Post Luncheon presentation
    Featuring a well-known analyst of the VC condition inthe US and elsewhere, this talk will examine the current venture capital environment. The speaker will discuss his assessment of the likely future of the industry. He will argue that the most dramatic changes are in the “upstream” side - with important consequences for the entrepreneur.
    2:00 PM Concurrent Mini Plenaries
    Primary Presentations:
    FOUR featured firms each allocated a 25 minute slot Full-Presentation Session FOUR:
    Location: John Hancock Room 201

    2:00 PM Moderator remarks: Robert J. Crowley, Massachusetts Technology Development Corporation, Boston, MA

    • 2:03 PM ComSense Technology Inc, Cleveland, OH; Robert Schmidt, Presenter
    • 2:30 PM Gibbard Research and Development Corporation, Haverhill MA; H. Frank Gibbard, Presenter
    • 3:00 PM Vista Engineering Inc, Birmingham, AL; Raymond Thompson, Presenter
    • 3:30 PM Zweave Inc, Boston, MA; David Buck, Presenter
    		Primary Presentations:
    FOUR featured firms each allocated a 25 minute slot. Full-Presentation Session FIVE::
    Location: George Washington Carver Room 202

    2:00 PM Moderator remarks: Lawrence S. Nannis, Levine, Katz, Nannis & Solomon, PC, Needham, MA

    • 2:03 PM Guardian Solutions Inc, Bradenton, FL; John Montelione, Presenter
    • 2:30 PM RemoteReality Corporation, Westborough MA; Mike Zwolinski, Presenter
    • 3:00 PM ImTelligenceŽ Inc, East Hartford, CT; Keith R. Reynolds, Presenter
    • 3:30 PM Securics Inc, Colorado Springs, CO; Terrance Boult, Presenter
    		Primary Presentations:
    FOUR featured firms each allocated a 25 minute slot. Full-Presentation Session SIX::
    Location: George Washington Room 302 (Third Floor)

    2:00 PM Moderator remarks: J. James Rudd, National Science Foundation, Arlington, VA

    • 2:03 PM Microvi Biotech LLC, Overland Park, KS; Wil Jacques, Presenter
    • 2:30 PM CryoFacets, Inc., Raleigh, NC; Howard Purdum, Presenter
    • 3:00 PM Phylogenetix Laboratories Inc., Overland Park, KS; Ronan Molloy, Presenter
    • 3:30 PM Biosomes, Inc, Wilmington, DE; Charles Saller, Presenter
    Roundtable Start-Up Clinic B
    Location: Library Third Floor    :
    With particular emphasis on the range of issues associated to the start-up, early-stage condition, by design this session is somewhat less tightly structured than the other full-blown presentation sessions in the time period.
    Each selected fi rm is assigned up to TWENTY minutes to make presentation, take questions and receive relevant feedback from the various funding sources and other professionals experienced in the start-up and early-stage condition. Again, the time allocation will be enforced and each presenter may use their time as they see fit.
    In this context, however, the Session Moderator and other professionals in the room have more fl exibility about how they run the session. Order of presentation will be retained but the amount of time between presentations may be longer with the balance of time used for working discussion of the common issues raised by the case presentations.

    2:00 AM Moderator remarks: Aaron Sandoski, Norwich Ventures, Cambridge, MA

    Presenting Firms:
    • AVANCEN, LLC, Ormond Beach, FL; Ned Buffington, Presenter
    • EMTAC Inc,Santa Barbara, CA; Russell Rising, Presenter
    • ThromboVision Inc., Houston, TX; Edward Teitel, Presenter
    • Gene Regulation Laboratories, Newton, MA; Susan P Perrine, Presenter

    4:00 PM Let me ask you this: an interactive Q/A
    involving several of the participating professionals
    4:30 PM Conference Concludes
    Networking reception